Last reviewed · How we verify
NCT03234751: BNP3
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects
Phase 1 trial testing Continous IV infusion of Nesiritide in Diabetes in 6 participants. Completed in 19 February 2020.
24 September 2018
Quick facts
| Lead sponsor | AdventHealth Translational Research Institute |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 6 |
| Start date | 13 July 2017 |
| Primary completion | 24 September 2018 |
| Estimated completion | 19 February 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Continous IV infusion of Nesiritide — full drug profile →
- Hyperinsulinemic euglycemic clamp — full drug profile →
- Placebo
Conditions studied
- Diabetes — all drugs for Diabetes →
Sponsor
AdventHealth Translational Research Institute
Who can join
Adults 40 to 65, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to compare the effects of nesiritide to placebo administered by a continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy, obese, insulin resistant individuals.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.
Friebe A, Kraehling JR, Russwurm M, Sandner P, et al · · 2023 · cited 5× · PMID 37079081 · DOI 10.1007/s00210-023-02484-8
Verify or expand the search:
- PubMed search for NCT03234751
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other AdventHealth Translational Research Institute trials
Trials by the same sponsor.
- NCT05820490 — ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks · completed
- NCT05773144 — Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer · NA · recruiting
- NCT05789433 — Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer · NA · recruiting
- NCT05379348 — Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment F · completed
- NCT05209100 — Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03234751 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AdventHealth Translational Research Institute
- Last refreshed: 10 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03234751.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing